The DOI matches its Crossref record; 49 of the 52 references it cites were found in a registry or an index.
Effective oral delivery of insulin in animal models using vitamin B12-coated dextran nanoparticles
Abstract
The potential utility of vitamin B12 carrier system for the oral delivery of conjugated peptides/proteins and enhancement of nanoparticles (NPs) transport has been demonstrated. The present study aims to optimize the effectiveness of VB12-NPs conjugates using different levels of cross-linking, linked with different VB(12)-coatings and evaluates in animal models to investigate an efficient insulin carrier. Amino alkyl VB12 derivatives suitable for oral delivery were synthesized at 5'hydoxy ribose and e-propionamide sites via carbamate and ester/amide linkages, and were coupled to succinic acid modified dextran NPs of varied cross-linking. VB12 binding was confirmed by XPS analysis, and was quantified by HPLC (4.0 to 5.7% w/w of NPs). These polydisperse NPs conjugates showed higher size, high insulin entrapment and faster insulin release with low levels of cross-linking. These VB12-NPs conjugates (150-300 nm) showed profound (70-75% blood glucose reductions) and prolonged (54 h) anti-diabetic effects with biphasic behaviour in STZ diabetic rats. NPs with the low levels of cross-linking were found to be superior carriers, and were more effective with VB12 derivatives of carbamate linkage. The pharmacological availability relative to SC insulin was found to be 29.4%, which was superior compared to NPs conjugate of ester linked VB12 (1.5 fold) and relatively higher cross-linked particles (1.1 fold). Further, the NPs carrier demonstrated a similar oral insulin efficacy in congenital diabetic mice (60% reduction at 20 h). Significant quantities of plasma insulin were found in both animal models (231 and 197 muIU/ml). At two investigated doses, the carrier system shows dose response. Pre-dosing with a large excess of free VB12 minimized the observed activity, indicating predominance of VB12 mediated uptake. It is concluded that VB12-dextran NPs conjugate is a viable carrier for peroral insulin delivery to treat diabetics.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In diabetic rats, these vitamin B12-NPs conjugate effectively and reduce the blood glucose level (~70–75%) for an extended period of time (54 h) with biphasic behavior.”
From Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles (2019) · cites this paper as [87]
Citations
Cites
Goodman & Gilman's The Pharmacological Basis of Therapeutics
Brunton, L. L. (1985) · Cited by 7,321
Goodman and Gilman's the Pharmacological Basis of Therapeutics
Stigelman, W. H., & Pharm, D. (1986) · Military Medicine · doi:10.1093/milmed/151.1.386 · Cited by 6,796
Joslin, E., & Marble, A. (1971) · Annals of Internal Medicine · doi:10.7326/0003-4819-103-5-820_3 · Cited by 1,049
Biodegradable Hydrogels for Drug Delivery
Park, H., Park, K., & Shalaby, W. S. W. (1993) · CRC Press eBooks · doi:10.1201/9780429259098 · Cited by 698
Pan, Y., Li, Y.-J., Zhao, H.-Y., Zheng, J.-M., Xu, H., Wei, G., Hao, J.-S., & Fu-de, C. (2002) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(02)00486-6 · Cited by 686
Biodegradable hydrogels in drug delivery
Kamath, K. R., & Park, K. (1993) · Advanced Drug Delivery Reviews · doi:10.1016/0169-409x(93)90027-2 · Cited by 541
Cui, F., Shi, K., Zhang, L., Tao, A., & Kawashima, Y. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.05.013 · Cited by 391
Damgé, C., Michel, C., Aprahamian, M., & Couvreur, P. (1988) · Diabetes · doi:10.2337/diab.37.2.246 · Cited by 390
Enteral Absorption of Insulin in Rats from Mucoadhesive Chitosan-Coated Liposomes
Takeuchi, H., Yamamoto, H., Niwa, T., Hino, T., & Kawashimà, Y. (1996) · Pharmaceutical Research · doi:10.1023/a:1016009313548 · Cited by 389
Yamamoto, A., Taniguchi, T., Rikyuu, K., Tsuji, T., Fujita, T., Murakami, M., & Muranishi, S. (1994) · Pharmaceutical Research · doi:10.1023/a:1018968611962 · Cited by 321
Research works printed but not linked: 1
- Uraizee, 2000, Development of a targeted mucoadhesive drug delivery system for the peroral administration of insulin, Drugs Made Ger., 43, 41
Cited by
Sorted by citations
Nicolas, J., Mura, S., Brambilla, D., Mackiewicz, N., & Couvreur, P. (2013) · Chem. Soc. Rev. · doi:10.1039/c2cs35265f · Cited by 1,270
pH-Responsive Nanoparticles for Drug Delivery
Gao, W., Chan, J. M., & Farokhzad, O. C. (2010) · Molecular Pharmaceutics · doi:10.1021/mp100253e · Cited by 1,060
Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles
Singh, A. P., Biswas, A., Shukla, A., & Maiti, P. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0068-3 · Cited by 645
Hua, S. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00524 · Cited by 527
Nano-encapsulation as a promising approach for targeted delivery and controlled release of vitamins
Katouzian, I., & Jafari, S. M. (2016) · Trends in Food Science & Technology · doi:10.1016/j.tifs.2016.05.002 · Cited by 536
Metadata
- Authors
- Chalasani, K. B., Russell-Jones, G. J., Jain, A. K., Diwan, P. V., & Jain, S. K.
- Affiliations
- Indian Institute of Chemical Technology (IN)
- Dr. Hari Singh Gour University (IN)
- Corresponding author
- Jain, Akhlesh K.
- Jain, Sanjay K.
- Venue
- Journal of Controlled Release
- Publisher
- Elsevier BV
- Published
- 2007-09
- Volume
- 122
- Issue
- 2
- Pages
- 141-150
- ISSN
- 0168-3659 (ISSN-L)
- OpenAlex
- W2093416811
- Cited by
- 257
- References
- 52
- Citations by year
- 2026: 3 · 2025: 10 · 2024: 4 · 2023: 16 · 2022: 20 · 2021: 20 · 2020: 26 · 2019: 10 · 2018: 12 · 2017: 15 · 2016: 17 · 2015: 11 · 2014: 22 · 2013: 19 · 2012: 20
- FWCI
- 4.89
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Controlled Release (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Council of Scientific and Industrial Research, India
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Drug Solubulity and Delivery Systems
- Keywords
- oral insulin delivery, vitamin B12, dextran nanoparticles, insulin, carbamate linkage, ester linkage, insulin secretion, blood glucose reduction, streptozotocin-induced diabetes, congenital diabetes
- MeSH terms
- Administration, Oral, Animals, Blood Glucose, Chemistry, Pharmaceutical, Cross-Linking Reagents, Dextrans, Diabetes Mellitus, Experimental, Diabetes Mellitus, Type 1, Dose-Response Relationship, Drug, Drug Carriers, Drug Compounding, Epichlorohydrin, Female, Hypoglycemic Agents, Insulin, Particle Size, Solubility, Species Specificity, Vitamin B 12, Mice, Inbred NOD, Rats, Wistar, Mice, Rats, Nanoparticles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
